Compare ANIK & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | ARMP |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 199.7M |
| IPO Year | 1996 | 1996 |
| Metric | ANIK | ARMP |
|---|---|---|
| Price | $20.25 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.00 | $17.50 |
| AVG Volume (30 Days) | 85.3K | ★ 106.9K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,819,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.01 | $2.75 |
| 52 Week High | $22.88 | $14.98 |
| Indicator | ANIK | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 40.10 |
| Support Level | $20.13 | N/A |
| Resistance Level | $22.70 | $5.63 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 79.82 | 38.87 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.